Gastrin-producing neuroendocrine tumor

Summary

Gastrin-producing neuroendocrine tumor (MONDO:0003523) is a cancer and 17 clinical trials. Top therapeutic interventions include edotreotide gallium ga-68, esomeprazole, and gefitinib. A subtype of digestive system neuroendocrine tumor, grade 1/2 — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 17

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastrin-producing neuroendocrine tumor
Mondo ID	MONDO:0003523
DOID	DOID:5577
ICD-11	1333125891
NCIT	C3050
UMLS	C0017150
MedGen	6551
GARD	0023546
Is cancer (heuristic)	yes

Also known as: G cell tumor · G cell tumour · G-cell gastrin producing tumor · G-cell gastrin producing tumour · G-cell tumor · G-cell tumour · gastrin cell tumor · gastrin secreting tumor · gastrin secreting tumour · gastrin-producing NET · gastrin-producing neuroendocrine tumor · gastrinoma · malignant gastrinoma

Disease family

This is a subtype of digestive system neuroendocrine tumor, grade 1/2. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system neuroendocrine neoplasm › digestive system neuroendocrine tumor, grade 1/2 › gastrin-producing neuroendocrine tumor

Related subtypes (9): small intestine neuroendocrine tumor, well differentiated, low or intermediate grade, esophageal neuroendocrine tumor, L-cell glucagon-like peptide-producing neuroendocrine tumor, gastric neuroendocrine tumor, well differentiated, low or intermediate grade, neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor, rectal neuroendocrine tumor, gallbladder neuroendocrine tumor, grade 1/2, pancreatic neuroendocrine tumor, intestinal neuroendocrine tumor G1

Subtypes (3): gastric gastrin-producing neuroendocrine tumor, pancreatic gastrin-producing neuroendocrine tumor, duodenal gastrin-producing neuroendocrine tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 17.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	12
PHASE1	3
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01824875	PHASE2	ACTIVE_NOT_RECRUITING	Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
NCT00001191	PHASE2	COMPLETED	The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid
NCT00075439	PHASE2	COMPLETED	Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
NCT00084461	PHASE2	TERMINATED	Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT00131911	PHASE2	COMPLETED	Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
NCT00454363	PHASE2	COMPLETED	Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
NCT01525082	PHASE2	COMPLETED	Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
NCT02031536	PHASE2	TERMINATED	Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
NCT02108782	PHASE2	WITHDRAWN	Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
NCT02259725	PHASE2	COMPLETED	Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
NCT02273752	PHASE2	TERMINATED	Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
NCT04915144	PHASE2	WITHDRAWN	177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
NCT00004074	PHASE1	COMPLETED	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
NCT00655655	PHASE1	COMPLETED	Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
NCT01204476	PHASE1	COMPLETED	Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
NCT03583528	Not specified	ACTIVE_NOT_RECRUITING	DOTATOC PET/CT for Imaging NET Patients
NCT00001240	Not specified	COMPLETED	Evaluating Patients With Abnormal Levels of Gastric Acid

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EDOTREOTIDE GALLIUM GA-68	4	1
ESOMEPRAZOLE	4	1
GEFITINIB	4	1
OCTREOTIDE ACETATE	4	1
OMEPRAZOLE	4	1
PANTOPRAZOLE	4	1
PAZOPANIB HYDROCHLORIDE	4	1
REGORAFENIB	4	1
ROMIDEPSIN	4	1
SORAFENIB	4	1
VATALANIB	3	2
CIXUTUMUMAB	2	1
DOVITINIB LACTATE	2	1
EDODEKIN ALFA	2	1
LUTETIUM LU177 EDOTREOTIDE	2	1
CHEMBL4066465	0	1